Replies to post #146855 on Cytodyn Inc (CYDY)

[justdafactss]

Which research paper, doctor, or scientist has stated with 100% certainty leronlimab caused a "Lazarus effect"?

Meaning a person walked into the hospital at deaths door and was proverbially playing tennis the next week after walking out of the hospital.

Time for CYDY to put up or shut up with the CD12 results.

The clinical trial says MORTALITY right?---

Primary Outcome Measures :
All-cause mortality at Day 28 [ Time Frame: Day 28 ]
Day 0 refers to the data of randomization/first treatment.
https://clinicaltrials.gov/ct2/show/NCT04347239?term=leronlimab&draw=2&rank=5

Clearly says MORTALITY, not topline, scrubbing or any of the other CYDY nonsense excuses.

Looks like Samsung demanded a penalty payment from CYDY---

WARRANT EXERCISE INDUCEMENT AGREEMENT

This Warrant Exercise Inducement Agreement (this “Agreement”), dated as of January , 2021, is by and between CytoDyn Inc., a Delaware corporation, (the “Company”) and the undersigned holder (the “Holder”) of warrants to purchase shares of the Company’s common stock, par value $0.001 per shares (the “Common Stock”), issued by the Company, as set forth on Schedule A (collectively, the “Warrants”).

2. Closing; Payment. Holder shall execute this Agreement and immediately wire the aggregate cash exercise price for such Warrants to the following bank account:



Bank Name: JPMorgan Chase Bank, N.A.
Bank Address: Business Banking, OR1-2013
4155 Mercantile Drive
Lake Oswego, Oregon 97035
ABA Number: xxxxxxxxxxx
A/C Name: CytoDyn Inc.
A/C Number: xxxxxxxxxxx
FBO:
See Schedule A
https://www.sec.gov/Archives/edgar/data/1175680/000119312521021786/d121529dex101.htm